Rigel Pharmaceuticals Inc
RIGLHealthcare|Biotechnology|USA
$42.55
-1.22 (-2.79%)
DCF (FCF)
$12.26
Tangible Book
$20.33
Graham Number
$92.54
About
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Stock Price
+117.1%(1Y)
Pipeline Summary
43 total trials9
Phase 1
28
Phase 2
6
Phase 3
2
Phase 4
Recruiting: 11Completed: 24Withdrawn: 3Terminated: 2ENROLLING_BY_INVITATION: 1NOT_YET_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Active Trials (11)
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
NCT06445959Mutant IDH1 Inhibitor Olutasidenib
Phase 1Phase 2Recruiting
Enrollment: 78 participants
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
NCT06233110Chronic Graft Versus Host Disease
Phase 1Recruiting
Enrollment: 30 participants
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT07471841IDH1 Mutation
Phase 2Recruiting
Enrollment: 25 participants
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264Low Risk Myelodysplastic Syndromes
Phase 1Phase 2Recruiting
Enrollment: 86 participants
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
NCT07130695Acute Myeloid Leukemia
Phase 1Recruiting
Enrollment: 15 participants
BioScore
4.6/10
Cautious
Ownership
Recent Insider Trades
Ali-Jackson KamilSELL
2026-06-222,500 shares @ $35
Ali-Jackson KamilSELL
2026-05-262,500 shares @ $29.17
MOOS WALTER HSELL
2026-02-204,000 shares @ $36.36
Schorno Dean LSELL
2025-02-053,770 shares @ $21.38
Santos David ASELL
2025-02-053,921 shares @ $21.38
Recent News
2026-07-07 13:00:05
2026-07-01 19:30:45
2026-07-01 13:01:01
2026-06-17 07:55:52
2026-06-16 21:00:04
Data last updated: Jul 12, 2026, 07:40 PM